Mankind Pharma Stock Screener | Share Price & Fundamental Analysis
MANKIND
Pharmaceuticals
Share Price NSE
₹2040.10
▲
22.40 (1.11%)
Share Price BSE
₹2040.35
▲
21.30 (1.05%)
Track Mankind Pharma share price live with TickJournal's free stock screener.
Analyze Mankind Pharma share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Mankind Pharma Market Cap
₹81,438.18 Cr.
MANKIND P/E Ratio (TTM)
45.73
Mankind Pharma P/B Ratio
5.39
EPS (TTM)
₹49.28
Dividend Yield
-
Debt to Equity
0.37
MANKIND 52 Week High
₹2696.50
Mankind Pharma 52 Week Low
₹1927.40
Operating Margin
22.00%
Profit Margin
12.75%
MANKIND Revenue (TTM)
₹3,333.00
EBITDA
₹933.00
Net Income
₹425.00
Total Assets
₹27,760.00
Total Equity
₹14,568.00
Mankind Pharma Share Price History - Stock Screener Chart
Screen MANKIND historical share price movements with interactive charts. Analyze price trends and patterns.
Mankind Pharma Company Profile - Fundamental Screener
Screen Mankind Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for MANKIND shares.
Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
RAMESH CHAND JUNEJA
ISIN
INE634S01028
Website
https://www.mankindpharma.com
Mankind Pharma Balance Sheet Screener
Screen MANKIND balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 27,760 | 11,963 | 9,715 | 9,148 | 6,373 |
| Current Assets | 6,988 | 6,568 | 4,328 | 4,407 | 3,907 |
| Fixed Assets | 19,005 | 4,545 | 4,251 | 3,588 | 1,664 |
| Liabilities | |||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 7,528 | 268 | 229 | 208 | 156 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 14,568 | 9,576 | 7,623 | 6,316 | 4,863 |
| Share Capital | 41 | 40 | 40 | 40 | 40 |
| Reserves & Surplus | 14,291 | 9,323 | 7,395 | 6,115 | 4,682 |
Mankind Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Mankind Pharma income statement and profit fundamentals.
Analyze MANKIND quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Mankind Pharma share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,333 | 3,653 | 3,791 | 3,643 | 2,517 | 2,976 | 3,173 | 3,286 | 2,103 | 2,642 | 2,772 | 2,682 | 1,764 | 2,200 | 2,457 |
| Expenses | 2,401 | 2,724 | 2,776 | 2,754 | 1,836 | 2,196 | 2,217 | 2,383 | 1,636 | 1,924 | 2,025 | 2,000 | 1,441 | 1,724 | 1,835 |
| EBITDA | 933 | 930 | 1,016 | 889 | 681 | 780 | 956 | 903 | 467 | 718 | 746 | 681 | 323 | 476 | 622 |
| Operating Profit % | 22.00% | 24.00% | 25.00% | 23.00% | 24.00% | 23.00% | 28.00% | 26.00% | 20.00% | 25.00% | 25.00% | 23.00% | 17.00% | 21.00% | 24.00% |
| Depreciation | 231 | 219 | 222 | 223 | 100 | 103 | 101 | 187 | 85 | 87 | 97 | 110 | 47 | 78 | 79 |
| Interest | 191 | 171 | 170 | 157 | 9 | 11 | 7 | 221 | 5 | 6 | 9 | 9 | 13 | 16 | 10 |
| Profit Before Tax | 511 | 541 | 624 | 509 | 572 | 666 | 849 | 495 | 377 | 625 | 641 | 562 | 263 | 382 | 533 |
| Tax | 86 | 96 | 104 | 95 | 95 | 123 | 190 | 111 | 84 | 130 | 130 | 103 | 70 | 84 | 110 |
| Net Profit | 425 | 445 | 520 | 414 | 477 | 543 | 659 | 385 | 294 | 494 | 511 | 460 | 193 | 298 | 423 |
| EPS | 10.19 | 10.62 | 12.39 | 9.90 | 11.76 | 13.39 | 16.31 | 9.46 | 7.13 | 12.15 | 12.51 | 11.33 | 4.74 | 7.30 | 10.48 |
Mankind Pharma Cash Flow Screener - Liquidity Fundamentals
Screen MANKIND cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|
| Operating Activities | 2,413 | 2,152 | 1,813 | 920 | 1,137 | 1,070 |
| Investing Activities | -12,624 | -2,081 | -1,052 | -1,369 | -1,222 | -436 |
| Financing Activities | 10,233 | 5 | -740 | 605 | -8 | -531 |
| Net Cash Flow | 22 | 77 | 22 | 156 | -92 | 103 |
Mankind Pharma Shareholding Pattern Screener
See Mankind Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Mankind Pharma promoter holding and ownership changes for MANKIND on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 72.70% | 72.68% | 72.67% | 72.66% | 74.88% | 74.87% | 74.87% | 72.71% |
| FII Holding | 12.92% | 13.07% | 12.84% | 11.34% | 9.87% | 11.58% | 12.37% | 13.34% |
| DII Holding | 11.48% | 11.50% | 11.92% | 13.25% | 11.14% | 9.95% | 9.90% | 11.06% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 1.64% | 1.52% | 1.36% | 1.52% | 1.22% | 1.46% | 1.55% | 1.60% |
| Other Holding | 1.26% | 1.23% | 1.21% | 1.23% | 2.89% | 2.15% | 1.31% | 1.30% |
| Shareholder Count | 180,597 | 179,549 | 170,347 | 177,539 | 135,116 | 153,450 | 163,854 | 172,431 |
Mankind Pharma Share Dividend Screener - Share Yield Analysis
Check Mankind Pharma dividend history with payout and yield data.
View Mankind Pharma dividend details including ex-dates and amounts for MANKIND stock.
Mankind Pharma Stock Index Membership
See which indices include Mankind Pharma stock.
Check MANKIND index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX BSEIPO
BSE INDEX LCTMCI
BSE INDEX LMI250
BSE INDEX LRGCAP
NIFTY 200
NIFTY 500
NIFTY HEALTHCARE
NIFTY LARGEMID250
NIFTY MIDCAP 100
NIFTY MIDCAP 150
NIFTY MIDSMALL INDIA CONSUMPTION
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY PHARMA
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 SHARIAH
Mankind Pharma Market Events Screener - Corporate Actions
Get Mankind Pharma corporate actions including splits, bonuses, and buybacks.
Check Mankind Pharma stock events that may affect MANKIND share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-02-03 | 2026-02-03 | Quarterly Result Announcement | NA | -8.73% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -2.59% |
| 2025-08-08 | 2025-08-08 | Dividend | ₹ 1.00 /share | -1.46% |
| 2025-08-07 | 2025-08-07 | Annual General Meeting | NA | 7.07% |
| 2025-07-31 | 2025-07-31 | Quarterly Result Announcement | NA | -0.10% |
| 2025-05-21 | 2025-05-21 | Quarterly Result Announcement | NA | 4.86% |
| 2025-01-23 | 2025-01-23 | Quarterly Result Announcement | NA | -8.15% |
| 2024-11-05 | 2024-11-05 | Quarterly Result Announcement | NA | 9.21% |
| 2024-08-09 | 2024-08-09 | Annual General Meeting | NA | -2.17% |
Mankind Pharma Competitors Screener - Peer Comparison
Screen MANKIND competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 398,098 | 37.12 | 54,729 | 9.71% | 10,980 | 37.98 |
| Divis Laboratories | 152,950 | 62.72 | 9,712 | 18.67% | 2,191 | 33.24 |
| Torrent Pharmaceuticals | 134,261 | 59.42 | 11,539 | 6.99% | 1,911 | 32.75 |
| Lupin | 102,899 | 22.29 | 22,910 | 13.74% | 3,306 | 47.35 |
| Dr Reddys Laboratories | 100,140 | 18.40 | 33,741 | 16.73% | 5,725 | 39.36 |
| Cipla | 95,019 | 21.27 | 28,410 | 7.12% | 5,291 | 26.86 |
| Zydus Life Science | 86,134 | 17.30 | 23,511 | 18.55% | 4,615 | 41.42 |
| Mankind Pharma | 81,438 | 45.73 | 12,744 | 20.90% | 2,007 | 41.40 |
| Aurobindo Pharma | 77,270 | 22.27 | 32,346 | 9.43% | 3,484 | 64.38 |
| Alkem Laboratories | 62,204 | 25.95 | 13,458 | 3.70% | 2,216 | 42.54 |
Mankind Pharma Company Announcements - News Screener
Screen MANKIND latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-03-30 | Closure of Trading Window | - |
| 2026-03-18 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-16 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-02-27 | Clarification Submitted By Mankind Pharma Limited | - |
| 2026-02-27 | Clarification sought from Mankind Pharma Ltd | - |
| 2026-02-26 | Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 | - |
| 2026-02-24 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-16 | Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 | - |
| 2026-02-09 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-02-09 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-03 | Compliances-Reg. 54 - Asset Cover details | - |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-03 | Board Meeting Outcome for Outcome Of Board Meeting Of Financial Results For Q3 FY26 | - |
| 2026-02-03 | Financial Result For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-01-16 | Announcement under Regulation 30 (LODR)-Credit Rating | - |